| Symbol | DYBTY |
|---|---|
| Name | DUALITY BIOTHERAPEUTICS INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | China Full floor, 11th Fl, Tower A, Datang Int China Construction Engineering Group |
| Telephone | +86 021-2601 8730 |
| Fax | — |
| — | |
| Website | https://en.dualitybiologics.com/ |
| Incorporation | KY |
| Incorporated On | 2019 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;Pink Limited |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: Hong Kong Stock Exchange |
| CIK | 0002085208 |
| Description | Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; and BeiGene, Ltd. to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC. Additional info from OTC: Additional info from Pink Limited: |
No news found.